Kulke Appointed Chief of Hematology/Oncology at BUMC

Boston University Medical Center has announced that Matthew Kulke, MD, will serve as its chief of the Section of Hematology/Oncology in the Department of Medicine, effective March 1, 2018. Kulke will also obtain the roles of deputy director of the BU-BMC Cancer Center, medical director of the Clinical Cancer Center at BMC, and the Zoltan Kohn Professor of Medicine at the Boston University School of Medicine.

Matthew Kulke, MD

Boston University Medical Center (BUMC) has announced that Matthew Kulke, MD, will serve as its chief of the Section of Hematology/Oncology in the Department of Medicine, effective March 1, 2018. Kulke will also obtain the roles of deputy director of the BU-BMC Cancer Center, medical director of the Clinical Cancer Center at BMC, and the Zoltan Kohn Professor of Medicine at the Boston University School of Medicine.

Kulke is currently the director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute (DFCI) and a professor of medicine at Harvard Medical School.

A national and international leader in clinical and translational studies, Kulke specializes in patients with gastrointestinal malignancies and neuroendocrine tumors. He served as the study chair for a national study with the Cancer and Leukemia Group B (CALGB) of pancreatic cancer therapies, which was funded by the National Cancer Institute. He has also published more than 100 peer-reviewed articles on neuroendocrine tumors.

He has received numerous awards for his accomplishments as a clinical investigator, including the George Canellos Award for Clinical Investigation, the Ruth Brufsky Award for Pancreatic Cancer Research, and the Discovery Fellowship at DFCI. He currently serves on the advisory board for the European Neuroendocrine Tumor Society, the executive committee of the North American Neuroendocrine Tumor Society, and chairs the Neuroendocrine Tumor Task Force for the National Cancer Institute.